<?xml version="1.0" encoding="UTF-8"?>
<notes id="n1">
 <title>Notes</title>
 <p>
  <bold>
   <italic>Data sharing.</italic>
  </bold> Qualified researchers may request access to individual patient level data through the clinical study data request platform (
  <ext-link ext-link-type="uri" xlink:href="http://www.clinicalstudydatarequest.com" xmlns:xlink="http://www.w3.org/1999/xlink">www.clinicalstudydatarequest.com</ext-link>). Further details on Roche’s criteria for eligible studies are available here (
  <ext-link ext-link-type="uri" xlink:href="https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx</ext-link>). For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (
  <ext-link ext-link-type="uri" xlink:href="https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm</ext-link>).
 </p>
 <p>
  <bold>
   <italic>Disclaimer.</italic>
  </bold> The views expressed in this manuscript are not necessarily those of the Department of Health and Social Care (DHSC), England.
 </p>
 <p>
  <bold>
   <italic>Financial support.</italic>
  </bold> This work was supported by F. Hoffmann-La Roche Ltd.
 </p>
 <p>
  <bold>
   <italic>Potential conflicts of interest.</italic>
  </bold> R. R., R. A. M. F., and A. D. M. E. O. have received research funding from F. Hoffmann-La Roche Ltd. P. L. A. F. receives funding from PREPARE Europe (EU FP7 grant 378 602525) and Takeda and was an invited speaker at scientific meetings sponsored by GlaxoSmithKline and Shire. D. K. has received research funding from F. Hoffmann-La Roche Ltd and GlaxoSmithKline and honoraria from GlaxoSmithKline and Sanofi. J. S. N.-V.-T. is currently seconded to the DHSC. R. W. receives support from the National Institutes of Health (NIH) and is on the Gilead Science Board of Directors. A. D. M. E. O. reports personal fees from Hoffman La Roche and GlaxoSmithKline; is the founder, chief service officer, and minor shareholder of Viroclinics Biosciences BV and C202; and reports EU and Coalition for Epidemic Preparedness Innovations grants outside the submitted work. M. S. received consultancy fees for the Influenza Resistance Information Study project from Hoffmann-La Roche Ltd. A. M. reports consulting fees from F. Hoffmann-La Roche Ltd. R. A. M. F. reports grants from H2020 COMPARE and the NIH National Institute of Allergy and Infectious Diseases/Centers of Excellence for Influenza Research and Surveillance during the conduct of the study. B. C. reports employment with stock from Roche Products Ltd. C. A. B . reports speakers honoraria from ViiV outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
 </p>
</notes>
